CMC Biologics has acquired XOMA's large-scale manufacturing operations and affiliated assets located in Berkeley, CA. Financial terms of the transaction were not disclosed.
The fully functional 31,000-sq.-ft. facility is a completely equipped biological manufacturing operation, including three 2,750L stainless steel bioreactors and two purification suites, as well as warehouse and office space. CMC Biologics expects to begin offering CMO services from this location immediately following the close of the transaction.
"We are very pleased to expand our clinical and commercial manufacturing operations to one of largest and most robust biotechnology clusters in the world," said Claes Glassell, chief executive officer of CMC Biologics. "Establishing a facility in the Bay Area complements our existing facilities located in Bothell, WA and in Copenhagen Denmark, and supports our continued growth and addresses the growing demand of our customers for cGMP clinical and commercial production of biopharmaceuticals."